Spine Art ECONOMIC

Target: Spineart SA Research date: 28 October 2026 Jurisdiction: Switzerland Corporate identifier: CHE-112.355.249 Domain: Economic

Supply Chain & Sourcing Relationships

Direct Israeli commercial relationships

Amos Gazit Ltd., an Israeli medical-equipment distributor, publicly lists SpineArt among the manufacturers represented in its medical-equipment business. Its own website maintains a dedicated SpineArt product category, establishing a publicly advertised commercial channel for Spineart medical devices in Israel as observed on 28 October 2026.^{1, 2}

The acting entities are Swiss manufacturer Spineart SA and Israeli distributor Amos Gazit Ltd.; the commercial channel is the distributor’s medical-equipment business, and the public communication appears on gazit.co.il. The earliest contract date, exact transaction values, and duration of the arrangement are undisclosed in the retrieved records. The relationship remained publicly advertised on 28 October 2026; actual order activity and contractual status on that date are unconfirmed.^{1, 3}

Amos Gazit’s SpineArt product-category page provides direct evidence of a medical-device distribution channel, rather than procurement of Israeli agricultural produce by Spineart. No public evidence identified of commercial relationships with Mehadrin, Hadiklaim, Galilee Export, Agrexco successors, or other Israeli agricultural exporters.¹

Third-party and indirect sourcing

Joinsmart Biomedical Co., Ltd., a Taiwanese medical-device distributor, identifies Swiss Spineart and Israeli manufacturer CarboFix as separate international partners. This establishes their appearance in the same distributor portfolio, but does not establish a direct supply, manufacturing, or procurement relationship between Spineart and CarboFix.⁴

Importer-of-record arrangements

No public evidence identified establishing whether Amos Gazit Ltd. or another business serves as the importer of record for Spineart devices entering Israel, or identifying the customs registration and contractual import structure.^{1, 2}

Seasonal sourcing

No public evidence identified of seasonal procurement, counter-seasonal purchasing, recurring agricultural imports, or Israeli-origin produce sourcing.^{1, 5}

Settlement sourcing and distribution

No public evidence identified of Spineart devices being supplied to a named settlement, settlement-based distributor, settlement hospital, or customer in the occupied West Bank, East Jerusalem, or occupied Golan Heights.^{1, 2}

Product Origin, Labeling & Regulatory Compliance

Manufacturing origin

Spineart SA identifies its operational headquarters in Switzerland and lists a manufacturing facility at 356 Rue de la Tour, Reignier-Esery, France. Its published locations also include offices in the United States, Germany, Spain, Italy, and the United Kingdom.⁶

In its 26 September 2025 corporate announcement, Spineart SA described a recently opened manufacturing facility in Reignier, France. The announcement also described expanded manufacturing capacity associated with the company’s global growth plans.⁷

Settlement-origin products

No public evidence identified that Spineart SA manufactures, procures, or markets products originating in Israeli settlements in the occupied West Bank, East Jerusalem, or Golan Heights.⁶

Country-of-origin compliance

No public evidence identified of a regulatory finding, customs enforcement action, product-labeling violation, or official investigation involving Spineart and Israeli or settlement-origin labeling.^{6, 8}

Corporate policy

Spineart SA’s published legal notices explain that product availability and applicable medical-device regulations vary by country. No public evidence identified of a company policy specifically addressing sourcing from, selling to, or labeling products manufactured in occupied territories.⁸

Investment, Capital & Financial Exposure

Direct investment in Israel

No public evidence identified of Spineart SA acquiring an Israeli manufacturer, constructing an Israeli facility, purchasing Israeli commercial real estate, or making a disclosed direct investment in an Israeli operating company.^{6, 9}

Acquired Israeli operating subsidiaries

No public evidence identified of an Israeli operating company acquired or controlled by Spineart SA. Consequently, no verified Israeli acquisition date, purchase price, ownership percentage, manufacturing location, employee count, revenue contribution, market share, or military/settlement relationship can be reported.^{6, 9}

Confirmed investment outside Israel

On 30 April 2024, Spineart announced a €10 million strategic investment in SpinEM Robotics, a developer of navigation technologies for spinal surgery. The parties also announced a development collaboration involving navigation and robotic-assistance technology.⁹

SpinEM Robotics independently identifies Spineart as an investor and describes its Odysseus robotic-surgery technology. Its website identifies Haventure, based in the Grenoble area of France, as a supporting organisation; no Israeli operating location is identified for SpinEM in the retrieved corporate disclosures.¹⁰

Transaction adviser Apparius separately identifies the €10 million investment in SpinEM Robotics. It describes the transaction as Spineart entering SpinEM’s share capital; the precise current ownership percentage and any majority-control rights were not established.¹¹

Additional technology relationships

Spineart SA identifies eCential Robotics as a partner in the development and use of open robotic surgical technologies. The company describes interoperability between Spineart surgical devices and eCential’s robotic platforms; no Israeli ownership or manufacturing element of that partnership was established.⁵

Capital investment and ownership

On 26 September 2025, Spineart SA announced a CHF 25 million capital increase funded by Gimv and EGS Beteiligungen AG. The announcement identifies both as existing investors and describes the capital as support for product development and international expansion.⁷

The same transaction was published through Gimv’s regulated press-release channel. The announcement identifies expansion in Europe and the United States and reports projected 2025 global revenue of approximately €140 million, with more than 360 employees worldwide.¹²

EGS Beteiligungen AG states that it is wholly owned by the Ernst Göhner Foundation and invests the foundation’s capital over the long term. This identifies a Swiss institutional ownership chain associated with Spineart’s financing.¹³

The Swiss Private Equity & Corporate Finance Association independently identifies EGS Beteiligungen AG as a Swiss institutional investment company focused on equity financing, with a geographical investment focus on Switzerland.¹⁴

Portfolio and shareholder exposure

Gimv and EGS Beteiligungen AG are identified investors, but the retrieved evidence does not establish the complete shareholder register or each investor’s percentage following the September 2025 financing. No public evidence identified of a qualifying Israeli sovereign-bond, Israeli arms-company, or settlement-enterprise investment attributable to Spineart SA or its named controlling principals.^{7, 12}

Corporate financing

On 15 September 2026, Swiss financial adviser IFBC announced that it had advised Spineart SA on refinancing and increasing existing credit facilities through a new multi-currency syndicated loan containing an accordion option. The announcement identifies Spineart SA as the borrower and IFBC as adviser; participating lenders and transaction amounts were not disclosed.¹⁵

No public evidence identified connecting this financing to Israeli sovereign bonds, Israeli war bonds, settlement enterprises, Israeli defence contractors, or Israeli government borrowers.¹⁵

Financing the Israeli state

No public evidence identified of Spineart underwriting Israeli sovereign debt, distributing Israel Bonds, underwriting Israeli state insurance liabilities, or directly lending to Israeli military or settlement enterprises.^{7, 15}

Constructive-notice dates

The April 2024 investment in SpinEM Robotics predates 19 July 2024. Spineart’s September 2025 capital increase and September 2026 refinancing occurred after both 19 July 2024 and November 2024, but neither published transaction identifies an Israeli state or settlement beneficiary.^{9, 7, 15}

Operational Presence & Market Activity

Israeli commercial market

Amos Gazit Ltd.’s publicly accessible SpineArt category establishes a channel through which Spineart medical devices are marketed in Israel. The distributor’s website was accessible and continued displaying the category on 28 October 2026.¹

The acting intermediary is Amos Gazit Ltd.; the product supplier is Spineart SA, and the public-facing promotional channel is gazit.co.il. The earliest and latest confirmed transaction dates, customer identities, sales revenues, and contract duration remain undisclosed; the ongoing observation concerns the public product listing.^{1, 2}

Physical operations

Spineart SA’s official location directory identifies its Swiss headquarters, French manufacturing facility, Dallas innovation centre, and international offices in the United States and Europe. No dedicated Israeli Spineart office is listed in that directory.⁶

United States subsidiary

Florida Department of State corporate-registration information reproduced by Bizprofile identifies SPINEART USA INC. as an active Delaware corporation registered in Florida, with its principal office in Laguna Hills, California. The registration identifies Jerome Trividic as president and CEO, Gino Poggiali as CFO, and Bassem Khoury as secretary, with the latest annual report shown in the retrieved record filed on 10 March 2025. The reproduced information was last updated on 12 October 2025; its status as of 28 October 2026 was not independently established.¹⁶

United Kingdom subsidiary

UK Companies House identifies SPINEART (UK) LTD, company number 08328402, as an active private limited company incorporated on 12 December 2012, with its registered office in Portsmouth, England.¹⁷

Companies House identifies Shane David George Aiken and other officers in the company’s statutory director records. These records establish UK corporate governance but do not establish an Israeli operating company or Israeli control.¹⁸

Employee presence

Spineart SA reported more than 360 employees worldwide in September 2025. Its current corporate presentation describes approximately 370 employees, seven international offices, and a headquarters in Geneva.^{7, 5}

No public evidence identified of a separately disclosed Israeli employee count, Israeli payroll, Israeli tax registrations, Israeli Preferred Technology Enterprise status, or a dedicated Israeli research centre.^{5, 6}

Market positioning

Spineart SA states that it operates in more than 60 countries and markets globally. Its public corporate presentation does not separately disclose Israel’s share of turnover, profitability, or medical-device sales.⁵

Public-sector and settlement customers

No public evidence identified establishing a named Israeli government tender, hospital procurement contract, IDF contract, Israeli Ministry of Defence contract, or settlement-specific customer involving Spineart products.^{1, 2}

Activity after 19 July 2024 and November 2024

The Amos Gazit SpineArt listing remained publicly accessible on 28 October 2026, after both reference dates. The earliest commercial transaction, most recent delivery, and whether contractual shipments continued throughout the intervening period were not established.¹

Corporate Structure & Foundational Ties

Founding and domicile

Spineart’s corporate history identifies its foundation in 2005 and describes Geneva, Switzerland, as its original headquarters location. The company identifies Jérôme Levieux and Stéphane Mugnier-Jacob as its co-founders.^{19, 5}

Spineart SA’s legal notices identify the Swiss entity as the publisher of its corporate website, registered in Geneva under identifier CHE-112.355.249, with its business address at Chemin du Pré-Fleuri 3, Plan-les-Ouates, Switzerland.⁸

Swiss company-information provider Moneyhouse independently identifies SpineArt SA as an active Swiss company registered on 11 May 2005, with registered identifier CHE-112.355.249.²⁰

No public evidence identified that Swiss Spineart SA was founded in Israel, maintains its headquarters in Israel, or has Israeli corporate tax residency.^{8, 19}

Named investors and institutional owners

Gimv - significant institutional investor: participated in the September 2025 capital increase and is represented in Spineart’s governance structure. Searches covered Israeli operating investments, defence exposure, settlement activity, and sovereign financing; no qualifying transaction attributable to Spineart was identified.^{7, 5}

EGS Beteiligungen AG - institutional investor: participated in the September 2025 financing and maintains representation in Spineart governance. Searches covered Israeli investments, defence exposure, settlement activity, and financial holdings; no qualifying transaction attributable to Spineart was identified.^{7, 13}

Ernst Göhner Foundation - ultimate owner of EGS Beteiligungen AG: the foundation controls EGS through full ownership. Searches covered Israeli portfolio exposure and settlement financing; no qualifying investment attributable to Spineart was identified.¹³

Named founders, executive leadership and governance

Jérôme Trividic - Spineart CEO: identified on the current executive committee and as president and CEO of SPINEART USA INC. in the reproduced Florida corporate-registration record. Searches covered Israeli business ownership, defence investments, settlement activity, and personal financial interests; no qualifying personal investment was identified.^{5, 16}

Stéphane Mugnier-Jacob - Spineart co-founder: identified on the company’s leadership pages. Searches covered Israeli corporate investments, defence relationships, and settlement activities; no qualifying personal investment was identified.^{5, 19}

Jérôme Levieux - Spineart co-founder: identified in company history and leadership disclosures. Searches covered Israeli investments, military-sector links, and settlement activities; no qualifying personal investment was identified.^{5, 19}

Gino Poggiali - Chief Administrative Officer and General Manager HQ: identified in current leadership and as CFO in the reproduced Florida corporate-registration record for SPINEART USA INC. Searches covered Israeli investments, defence relationships, and Israeli operational management; no qualifying Israeli personal investment was identified.^{5, 16}

Bart Diels - Gimv representative: identified by Spineart as a board member and by the 2025 financing announcement as a Gimv managing partner. Searches covered Israeli investments and defence-sector relationships; no qualifying personal transaction was identified.^{5, 12}

Gautier Lefebvre - Gimv representative: identified in Spineart governance and the 2025 investor announcement. Searches covered Israeli portfolio investments and defence or settlement relationships; no qualifying personal transaction was identified.^{5, 12}

Kevin Klein - Gimv partner and Spineart board observer: Gimv’s professional biography explicitly identifies his involvement with Spineart. Searches covered Israeli investments and defence or settlement relationships; no qualifying personal transaction was identified.²¹

Christian Pfab - EGS Beteiligungen representative: identified on Spineart’s governance page and in the 2025 capital-increase announcement. Searches covered Israeli investments, defence-sector interests, and settlement activity; no qualifying personal transaction was identified.^{5, 12}

Dominik Sauter - EGS Beteiligungen representative: identified in Spineart’s published governance records. Searches covered Israeli investment and settlement-sector activity; no qualifying personal transaction was identified.⁵

Jean-Philippe Favre - minority-shareholder representative: identified in Spineart’s governance disclosures. Searches covered Israeli investments, defence companies, and settlement activities; no qualifying personal transaction was identified.⁵

Alessia Erlingher - Chief Commercial Officer: identified in Spineart’s current executive committee. Searches covered Israeli commercial arrangements, military procurement, and personal investments; no qualifying personal investment was identified.⁵

Guillaume Amblard - Chief Product Officer: identified in the current executive committee. Searches covered Israeli product-development partnerships, technology investments, and defence relationships; no qualifying personal investment was identified.⁵

Max Lok - Executive VP RAQA: identified in Spineart’s executive committee. Searches covered Israeli medical-device registrations, partnerships, and financial interests; no qualifying personal investment was identified.⁵

Yohan Stalder - Executive VP of Operations: identified in Spineart’s executive committee. Searches covered Israeli manufacturing, sourcing, and defence-supply relationships; no qualifying personal investment was identified.⁵

Stephan Cori - Executive VP of Finance: identified in the executive committee. Searches covered Israeli financial holdings, lending relationships, and investment activity; no qualifying personal investment was identified.⁵

Laurent Nodé-Langlois - Chief Technology Officer: identified in Spineart leadership. Searches covered Israeli technology investments, defence-sector partnerships, and operational interests; no qualifying personal investment was identified.⁵

Additional identified operating entities

Spineart USA Inc. - the US operating company, identified as active in Florida corporate-registration information reproduced by Bizprofile, with a California principal-office address. The reproduced information was last updated in October 2025. Searches covered Israeli procurement and defence relationships; no qualifying Israeli transaction was identified.¹⁶

Spineart (UK) Ltd - UK operating company, established in December 2012. Searches covered Israeli investments, procurement, and settlement commerce; no qualifying Israeli transaction was identified.¹⁷

Spineart Deutschland GmbH - German commercial operation appearing in Spineart’s locations directory. Searches covered Israeli sourcing, investments, and defence relationships; no qualifying Israeli transaction was identified.⁶

Spineart España SLU - Spanish commercial operation appearing in the official locations directory. Searches covered Israeli sourcing, investments, and defence relationships; no qualifying Israeli transaction was identified.⁶

Spineart Italia S.R.L. - Italian commercial operation appearing in the official locations directory. Searches covered Israeli sourcing, investments, and defence relationships; no qualifying Israeli transaction was identified.⁶

SpinEM Robotics SAS - investee rather than a verified wholly owned subsidiary: the published transaction confirms Spineart’s €10 million investment during April 2024. Searches covered Israeli ownership, defence-industry contracts, and settlement involvement; no qualifying Israeli transaction was identified.^{9, 10}

eCential Robotics - technology partner rather than a verified Spineart subsidiary: the published relationship concerns surgical navigation and robotics. Searches covered Israeli ownership, procurement, and defence relationships; no qualifying Israeli transaction was identified.⁵

UK significant-control filings

Companies House identifies Gino Poggiali as an active person with significant influence or control over SPINEART (UK) LTD, notified on 1 August 2022. Previous significant-control entries for Jérôme Trividic, Stéphane Mugnier-Jacob, and Jérôme Levieux show cessation dates in 2022; these records concern the UK company and do not establish corresponding percentages of ownership in Swiss Spineart SA.²²

Israeli-nexus floor: founding, control, residency and ownership

Founded in Israel: No; the documented founding location is Geneva, Switzerland, in 2005.¹⁹

Headquarters or principal place of management in Israel: No; the published headquarters is in Switzerland.^{6, 8}

Israeli tax residency or Preferred Technology Enterprise status: no public evidence identified.⁸

Beneficial ownership or control by Israeli capital: no public evidence identified; the publicly identified institutional investors are Gimv and EGS Beteiligungen AG.^{7, 13}

State and structural governance

No public evidence identified of an Israeli government ownership stake, state-appointed Spineart director, Israeli government golden share, Israeli defence-industry veto holder, or constitutional restriction tying Spineart to Israeli state policy.^{5, 8}

Profit Repatriation & Economic Contribution

Global revenue

Spineart SA’s September 2025 financing announcement projected approximately €140 million in global revenue for 2025. The company reported five years of average annual growth of approximately 16% at that time. This figure was a projection when announced, rather than an audited full-year revenue result.^{7, 12}

Israeli revenue

Amos Gazit Ltd.’s SpineArt product listing establishes an Israeli commercial distribution channel. No public evidence identified quantifying Spineart SA’s revenue attributable to Israel, sales volumes through Amos Gazit, or the proportion of global turnover generated in the Israeli market.^{1, 2}

Profit repatriation

No public evidence identified quantifying payments by Amos Gazit Ltd. to Spineart SA, Israeli distributor profits, withholding taxes, royalties, intercompany transfers, or the repatriation of profits between Israeli and Swiss entities.^{1, 8}

Domestic tax contribution

Spineart SA is legally registered in Switzerland, while the Israeli product relationship is publicly represented through Amos Gazit Ltd. No public evidence identified of Spineart SA paying Israeli corporate income tax, holding Israeli tax residency, or receiving Israeli tax incentives.^{8, 1}

Economic ecosystem role

Spineart SA describes itself as a global medical-device manufacturer operating across more than 60 markets. No public evidence identified assigning Spineart a quantified position within Israel’s medical-device market or identifying it as a nationally significant Israeli employer, infrastructure operator, defence supplier, or government-designated strategic enterprise.⁵

Investor and financing flows

The 2025 CHF 25 million capital increase provided growth funding to Spineart SA from Gimv and EGS Beteiligungen AG. The identified recipient was the Swiss target company; the published documents do not identify an Israeli state, financial institution, or Israeli operating company as the beneficiary of that transaction.^{7, 12}

The September 2026 syndicated facility was arranged for Spineart SA’s international financing needs. The retrieved announcement does not identify an Israeli lender, Israeli collateral, Israeli government guarantee, or financing arrangement supporting an Israeli settlement enterprise.¹⁵

Public market relationship after November 2024

As of 28 October 2026, Amos Gazit’s Israeli website continued to present SpineArt as a medical-equipment product category. The public listing establishes continuing visibility to the website’s Israeli audience; transaction frequency, product deliveries, customer locations, and revenue after November 2024 remain unverified.^{1, 3}